Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
1.
ESMO Open ; 8(6): 101609, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37879233

RESUMEN

BACKGROUND: Combined use of inhibitors of mammalian target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF-2) receptors is a potential strategy to overcome resistance to either class of drugs when used alone. PATIENTS AND METHODS: We designed a phase 1 trial to test the drug combination of a multikinase VEGF receptor 2 inhibitor, vandetanib, and an mTOR inhibitor, everolimus, in a pediatric and young adult patient cohort with advanced cancers. Exceptional responders were probed for tumor mutational profile to explore possible molecular mechanisms of response. RESULTS: Among 21 enrolled patients, clinical benefit was observed in 38% (one patient with partial response and eight patients with stable disease) with a median progression-free survival of 3.3 months. The most common treatment-related adverse event was rash (n = 13). Other treatment-related toxicities included diarrhea, fatigue, hypertension, QT prolongation, hypertriglyceridemia/hypercholesterolemia, transaminitis, thrombocytopenia, and weight loss. None of the patients experienced dose-limiting toxicities. Three exceptional responders were analyzed and were found to harbor genetic alterations including kinase insert domain receptor (KDR) Q472H mutation, EWSR1-CREB3L1, CDKN2A/B loss, and ASPL/ASPSCR1-TFE3 fusion. CONCLUSIONS: The combination of vandetanib and everolimus showed early activity and tolerable toxicity profile in pediatric patients with advanced cancers.


Asunto(s)
Everolimus , Neoplasias , Humanos , Adulto Joven , Adolescente , Niño , Everolimus/efectos adversos , Factor A de Crecimiento Endotelial Vascular , Neoplasias/tratamiento farmacológico , Neoplasias/genética , Sirolimus/efectos adversos , Piperidinas/efectos adversos , Quinazolinas/efectos adversos
2.
Pediatr Surg Int ; 32(1): 71-3, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26500075

RESUMEN

PURPOSE: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been used in adults with ovarian carcinoma proving overall survival benefit in randomized trials, but measured in months. Diffuse peritoneal disease from pediatric type ovarian tumors is rare. We applied CRS and HIPEC to pediatric girls with diffuse peritoneal disease as part of a clinical trial. METHODS: In all patients complete cytoreduction was followed by HIPEC using 100 mg/m2 of cisplatin for 90 min in a closed technique. All received neoadjuvant chemotherapy. Patients with disease outside of the abdominal cavity were excluded. RESULTS: Of 101 pediatric CRS and HIPEC operations, 8 had ovarian primary tumors and multifocal peritoneal disease. There were three yolk sac tumors (germ cell, mixed teratoma), one Sertoli­Leydig, one PNET of the ovary, one choriocarcinoma, one juvenile granulosa cell tumor and one adenocarcinoma. Age ranged 4­18 years. Three of the 8 (37 %) recurred and died. The remaining 63 % are disease free 2­6 years post HIPEC. Overall survival and relapse-free survival in this cohort was 64 and 62 %, respectively [CI 0.64 (0.34, 1); 0.62 (0.37, 1)]. CONCLUSIONS: This is the first report of CRS and HIPEC in pediatric ovarian tumors. HIPEC may be effective in pediatric-type ovarian tumors. More study is needed in a larger cohort.


Asunto(s)
Procedimientos Quirúrgicos de Citorreducción , Hipertermia Inducida , Neoplasias Ováricas/complicaciones , Neoplasias Ováricas/terapia , Enfermedades Peritoneales/complicaciones , Adolescente , Antineoplásicos/uso terapéutico , Quimioterapia Adyuvante , Cisplatino/uso terapéutico , Terapia Combinada , Femenino , Humanos , Terapia Neoadyuvante , Ovario/cirugía , Cavidad Peritoneal , Enfermedades Peritoneales/terapia , Peritoneo , Análisis de Supervivencia , Resultado del Tratamiento
3.
Clin Cancer Res ; 17(3): 611-9, 2011 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-21127194

RESUMEN

PURPOSE: This pediatric phase I study was designed to identify the doses of RG1507, a monoclonal antibody against the Type 1 Insulin-like Growth Factor Receptor (IGF1R), that achieves exposures equivalent to those achieved in adults at recommended doses. EXPERIMENTAL DESIGN: Children with relapsed or refractory solid tumors were treated using the same doses and administration schedules of RG1507 (3 and 9 mg/kg/wk, and 16 mg/kg every 3 weeks [q3W]) as those studied in adults. Detailed pharmacokinetic (PK) sampling was performed after the first dose; selected peak and trough levels were subsequently obtained. Target exposures were ≥85% of mean areas under concentration x time curves (AUCs) in adults at doses of 9 mg/kg/wk and 16 mg/kg q3W. A maximum tolerated dose could be identified if dose-limiting toxicities (DLT) occurred. RESULTS: Thirty-one evaluable patients aged 3-17 years were enrolled at 3 mg/kg/wk (n = 3), 9 mg/kg/wk (n = 18), or 16 mg/kg q3W (n = 10). There were no DLTs. At 9 mg/kg/wk the mean AUC(0-7d) (21,000 µg h/mL) exceeded the target (16,000 µg h/mL). At 16 mg/kg q3W, the mean AUC(021d) (70,000 µg h/mL) exceeded the target (59,400 µg h/mL). Clearance normalized to body weight was age dependent. There were no objective responses. Seven patients had stable disease for >12 weeks, including two patients with osteosarcoma with stable disease for 52+ and 78+ weeks. CONCLUSIONS: The recommended doses of RG1507 in children with solid tumors are 9 mg/kg/wk and 16 mg/kg q3W. This flexible design is well suited for trials of agents associated with limited toxicity.


Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Receptor IGF Tipo 1/antagonistas & inhibidores , Adolescente , Anticuerpos Monoclonales/farmacocinética , Niño , Preescolar , Resistencia a Antineoplásicos , Femenino , Humanos , Masculino , Recurrencia
5.
Cancer ; 92(6): 1550-5, 2001 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-11745234

RESUMEN

BACKGROUND: The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas. METHODS: The medical records of 43 consecutive patients with soft tissue or bone sarcomas who were treated with concurrent IFX and EBRT were reviewed. RESULTS: The median patient age was 20 years. Histologies were rhabdomyosarcoma (n = 16 patients), Ewing sarcoma (n = 10 patients), malignant fibrous histiocytoma (n = 9 patients), and other soft tissue sarcomas (n = 8 patients). Thirty-one patients (72%) had localized disease, and 12 patients (28%) had synchronous local and distant disease. Treatment consisted of EBRT (median dose, 50.4 gray [Gy]) with concomitant IFX (median dose per cycle, 10.2 g/m(2)). All patients with Ewing sarcoma or rhabdomyosarcoma received additional concurrent chemotherapy. Twenty-six patients (60%) received two or more cycles of IFX, and 17 patients (40%) were treated with one cycle of IFX and EBRT. The incidences of World Health Organization Grade 3 and Grade 4 toxicities were 29% (21 of 73 cycles) and 22% (16 of 73 cycles), respectively. Grade 4 systemic toxicities included leukopenia (n = 14 patients), neurotoxicity (suicidal ideation; n = 1 patient), and diarrhea (n = 1 patient). Confluent moist desquamation (Grade 3) occurred in nine patients in the treatment field; no patient experienced Grade 4 local toxicity. Among 14 patients who were treated preoperatively, 2 patients (14%) had a pathologic complete response, and 6 patients (43%) had a pathologic near-complete response (> or = 90% necrosis). CONCLUSIONS: Local and systemic toxicities after the administration of therapeutic doses of IFX with concomitant EBRT appear comparable to those observed with either treatment alone. These results support the design of prospective studies evaluating concurrent ifosfamide and radiation therapy for patients with sarcomas.


Asunto(s)
Antineoplásicos Alquilantes/administración & dosificación , Neoplasias Óseas/terapia , Ifosfamida/administración & dosificación , Sarcoma/terapia , Neoplasias de los Tejidos Blandos/terapia , Adulto , Anciano , Niño , Preescolar , Terapia Combinada , Femenino , Histiocitoma Fibroso Benigno/terapia , Humanos , Lactante , Masculino , Persona de Mediana Edad , Rabdomiosarcoma/terapia , Sarcoma de Ewing/terapia , Resultado del Tratamiento
6.
J Clin Oncol ; 19(11): 2812-20, 2001 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-11387352

RESUMEN

PURPOSE: To determine whether consolidation therapy with high-dose melphalan, etoposide, and total-body irradiation (TBI) with autologous stem-cell support would improve the prognosis for patients with newly diagnosed metastatic Ewing's sarcoma (ES). PATIENTS AND METHODS: Thirty-two eligible patients with newly diagnosed ES metastatic to bone and/or bone marrow were enrolled onto this study. Treatment was initially comprised of five cycles of induction chemotherapy (cyclophosphamide, doxorubicin, and vincristine alternating with ifosfamide and etoposide) and local control. Peripheral-blood stem-cell collection was performed after the second cycle of chemotherapy, with delay if the bone marrow was persistently involved. If patients had a good response to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, and stem-cell support. RESULTS: Of the 32 eligible patients, 23 proceeded to high-dose therapy consolidation. Of the nine patients who did not proceed to consolidation, four were secondary to progressive disease and two were secondary to toxicity. Three patients died from toxicity during the high-dose phase of the therapy. The majority of the patients who underwent high-dose consolidation therapy experienced relapse and died with progressive disease. Two-year event-free survival (EFS) for all eligible patients is 20%. The 2-year post-stem-cell reconstitution EFS for the subset of 23 patients who received consolidation therapy is 24%. Analysis of peripheral-blood stem-cell collections by molecular techniques for minimal residual disease showed contamination of at least some samples by tumor cells in all three patients with available data. CONCLUSION: Consolidation with high-dose melphalan, etoposide, TBI, and autologous stem-cell support failed to improve the probability of EFS in this cohort of patients with newly diagnosed metastatic ES.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/terapia , Trasplante de Células Madre Hematopoyéticas , Sarcoma de Ewing/terapia , Irradiación Corporal Total , Adolescente , Adulto , Neoplasias Óseas/patología , Niño , Preescolar , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Etopósido/administración & dosificación , Femenino , Humanos , Lactante , Masculino , Melfalán/administración & dosificación , Metástasis de la Neoplasia , Pronóstico , Sarcoma de Ewing/patología , Trasplante Autólogo , Resultado del Tratamiento
8.
Oncologist ; 5(6): 445-53, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11110595

RESUMEN

Hepatoblastoma is the most common primary liver tumor in children, accounting for just over 1% of pediatric cancers. The etiology is unknown, but it has been associated with Beckwith-Weidemann syndrome, familial adenomatosis polypi, and low birth weight. The primary treatment is surgical resection, however, chemotherapy plays an important role by increasing the number of tumors that are resectable. The prognosis for patients with resectable tumors is fairly good, however, the outcome for those with nonresectable or recurrent disease is poor.


Asunto(s)
Hepatoblastoma/terapia , Neoplasias Hepáticas/terapia , Niño , Hepatoblastoma/diagnóstico , Hepatoblastoma/patología , Humanos , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/patología , Estadificación de Neoplasias
9.
J Clin Oncol ; 17(9): 2670-75, 1999 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10561340

RESUMEN

PURPOSE: To review the outcome for all patients with ovarian dysgerminoma treated at the M.D. Anderson Cancer Center who received bleomycin, etoposide, and cisplatin (BEP) and to assess the menstrual and reproductive function of those who received conservative treatment. PATIENTS AND METHODS: Clinical information was abstracted from the medical record. Patients completed a detailed questionnaire about menstrual and reproductive function; those who did not return the questionnaire were interviewed by telephone. RESULTS: Twenty-six patients were identified as having been treated with BEP chemotherapy for pure ovarian dysgerminoma from January 1984 to January 1998. Their median age was 19.5 years (range, 7 to 32 years). Sixteen patients underwent fertility-sparing surgery in the form of unilateral salpingo-oophorectomy. At a median follow-up time of 89 months, 25 (96%) of the 26 patients remained continuously disease-free. One patient apparently developed a second primary dysgerminoma in her remaining ovary after BEP and was clinically disease-free after further treatment. Of the 16 patients who underwent fertility-sparing surgery, one was lost to follow-up when she was pregnant, and one was still premenarchal. Of the remaining 14 patients, 10 (71%) maintained their normal menstrual function during and after chemotherapy, and 13 (93%) had returned to their prechemotherapy menstrual pattern at the time of the questionnaire. Five pregnancies have occurred thus far, and two patients have had difficulty conceiving. CONCLUSION: Most patients with metastatic dysgerminoma can expect cure with maintenance of normal reproductive function when treated with conservative surgery and BEP chemotherapy.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Disgerminoma/tratamiento farmacológico , Ciclo Menstrual/efectos de los fármacos , Neoplasias Ováricas/tratamiento farmacológico , Índice de Embarazo , Adolescente , Adulto , Bleomicina/administración & dosificación , Niño , Cisplatino/administración & dosificación , Supervivencia sin Enfermedad , Disgerminoma/cirugía , Etopósido/administración & dosificación , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Primarias Secundarias/tratamiento farmacológico , Neoplasias Ováricas/cirugía , Ovariectomía , Estudios Retrospectivos
11.
Cancer Res ; 58(23): 5298-300, 1998 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-9850052

RESUMEN

Numerous chemotherapeutic agents act via stabilization of a topoisomerase (topo) II-DNA complex. HL-60/AMSA, a human leukemia cell line, is resistant to intercalator-mediated DNA complex formation and cytotoxicity. HL-60/AMSA contains a mutant form of topo IIalpha that was thought to explain this resistance. However, our present data show that expression of topo IIbeta RNA in HL-60/AMSA is only 10% of that in HL-60, and topo IIbeta protein levels are undetectable. Southern analysis of topo IIbeta shows no differences in gene dosage between the two cell lines but does show differences in the restriction patterns. These data suggest that decreased topo IIbeta expression may contribute to the intercalator resistance of HL-60/AMSA cells.


Asunto(s)
Amsacrina/farmacología , Antineoplásicos/farmacología , ADN-Topoisomerasas de Tipo II , ADN-Topoisomerasas de Tipo II/deficiencia , ADN-Topoisomerasas de Tipo II/genética , Isoenzimas/genética , Antígenos de Neoplasias , Northern Blotting , Southern Blotting , ADN-Topoisomerasas de Tipo II/biosíntesis , ADN-Topoisomerasas de Tipo II/metabolismo , Proteínas de Unión al ADN , Resistencia a Antineoplásicos , Células HL-60/efectos de los fármacos , Células HL-60/enzimología , Humanos , Immunoblotting , Isoenzimas/biosíntesis , Isoenzimas/metabolismo , Mutación , Fenotipo , ARN Mensajero/metabolismo
12.
Biochem Biophys Res Commun ; 232(3): 608-12, 1997 Mar 27.
Artículo en Inglés | MEDLINE | ID: mdl-9126321

RESUMEN

Several chemotherapeutic agents act via inhibition of topoisomerase (topo) II activity. Topo II levels appear to correlate with drug sensitivity in vivo. The DNA immediately 5' to the topo II alpha coding region contains five potentially regulatory inverted CCAAT boxes (ICB). Electrophoretic mobility shift assays (EMSA) using oligomers containing the wild type forms of these ICBs show specific DNA-protein binding. Mutations in these ICBs result in loss of protein binding. EMSA competition studies indicate that the four most 3' ICBs (1-4) bind to the same protein(s), while the most 5' ICB (5) binds to a different protein(s). EMSA supershift assays with antibodies to two known CCAAT binding proteins, CBF and CEB/P, indicate that ICBs 1-4 are binding to CBF, but ICB 5 is not bound by either of these proteins.


Asunto(s)
ADN-Topoisomerasas de Tipo II/genética , Isoenzimas/genética , Regiones Promotoras Genéticas , Antígenos de Neoplasias , Secuencia de Bases , Sitios de Unión/genética , Unión Competitiva , ADN/genética , ADN/aislamiento & purificación , ADN/metabolismo , Proteínas de Unión al ADN , Electroforesis en Gel de Poliacrilamida , Células HL-60 , Humanos , Mutación , Unión Proteica
13.
Br J Cancer ; 73(11): 1373-80, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8645582

RESUMEN

The human brain tumour cell line HBT20 is intrinsically resistant to etoposide and does not express mdr-1 mRNA. These studies were conducted to determine whether transfecting a Drosophila (D) topoisomerase II (topo II) gene into HBT20 cells could increase their sensitivity to etoposide. A D-topo II construct in a pMAMneo vector under the control of a mouse mammary tumour virus (MMTV) promoter was transfected into HBT20 cells. The gene is inducible by dexamethasone (Dex). The growth rate of the transfected cells and percentage of the cells in G1, S and G2M was no different than the parental cells. Survival after etoposide exposure (10 microM x 2 h) was measured by colony formation. Parental cells and cells transfected by pMAMneo vector alone showed no enhanced etoposide sensitivity after 24 h of Dex stimulation. By contrast, D-topo II transfected cells were sensitised 3-fold when etoposide treatment was preceded by 24 h Dex stimulation. Northern blotting and Western blotting confirmed that Dex had induced D-topo II expression in the sensitised cells. However, in D-topo II-transfected cells increasing the duration of Dex stimulation to 48 h eliminated the sensitisation to etoposide although increased MMTV promoter activity and expression of the D-topo II gene persisted. Measurement of endogenous human topo-II mRNA and protein revealed a decrease after Dex exposure of greater than 24 h. At these distal times, the total cellular topo II levels (endogenous + exogenous) may be decreased, which may explain why increased sensitivity to etoposide could no longer be demonstrated. This model suggests that D-topo II gene transfection can sensitise de novo resistant HBT20 cells to etoposide but that the time frame of that sensitisation is limited.


Asunto(s)
Antineoplásicos/toxicidad , ADN-Topoisomerasas de Tipo I/genética , Resistencia a Antineoplásicos , Etopósido/toxicidad , Transfección , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/deficiencia , Amsacrina/toxicidad , Animales , Neoplasias Encefálicas/genética , Ciclo Celular/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Cisplatino/toxicidad , ADN-Topoisomerasas de Tipo I/biosíntesis , Dexametasona/farmacología , Doxorrubicina/toxicidad , Drosophila/enzimología , Resistencia a Múltiples Medicamentos/genética , Vectores Genéticos , Humanos , Cinética , Virus del Tumor Mamario del Ratón , Ratones , Proteínas Recombinantes/biosíntesis , Células Tumorales Cultivadas , Ensayo de Tumor de Célula Madre
14.
Am J Surg ; 170(6): 606-8, 1995 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-7492010

RESUMEN

PURPOSE: To investigate the frequency, presentation, clinical management, and prognosis of appendiceal carcinoid tumors in children. METHOD: A review of our institution's experience over 50 years. RESULTS: Twenty-two patients below the age of 20 presented with appendiceal carcinoid tumor. The mean age at presentation was 14.6 years. Twelve patients presented with symptoms of appendicitis. No tumor was > 2.0 cm in size. Only 2 patients underwent resection beyond appendectomy. No patient had recurrent or metastatic carcinoid tumor, and all but 1 patient (who died of ovarian choriocarcinoma) are alive without evidence of carcinoid tumors 1.5 to 30 years after diagnosis. CONCLUSIONS: Appendiceal carcinoid tumors in children are rarely life-threatening and the incidence of large tumors (> 2.0 cm) is very low. The role of right hemicolectomy in large (> 2.0 cm) tumors is questionable in this age group.


Asunto(s)
Neoplasias del Apéndice , Tumor Carcinoide , Adolescente , Adulto , Neoplasias del Apéndice/diagnóstico , Neoplasias del Apéndice/cirugía , Tumor Carcinoide/diagnóstico , Tumor Carcinoide/cirugía , Niño , Femenino , Humanos , Masculino
15.
Clin Cancer Res ; 1(11): 1391-7, 1995 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-9815936

RESUMEN

We characterized three human brain tumor cell lines (D54, HBT-20, and HBT-28) with respect to resistance to etoposide (VP-16), a topoisomerase II-reactive drug. All three cell lines were inherently resistant to VP-16 when compared to other human cell lines, with D54 showing the greatest resistance using colony formation assays. Resistance to VP-16 has been attributed to decreased drug uptake and changes in topoisomerase II; however, drug uptake and topoisomerase II protein levels (immunoblot) were no lower in D54 than in HBT-20 and HBT-28, cell lines relatively more sensitive to VP-16. More to the point, measurement of topoisomerase II-mediated DNA cleavage of cellular DNA after treatment with VP-16 showed that the topoisomerase II in these cells was active. These data indicate mechanisms other than those attributable to decreased drug uptake or altered topoisomerase II exist for clinical resistance to VP-16. VP-16-induced DNA cleavage has been associated with apoptosis in some cell lines; however, neither DNA laddering nor morphological changes characteristic of apoptosis were detected in these cell lines after treatment with VP-16. Bcl-2 and mutant p53 were present in these cells. Either of these conditions can prevent apoptosis and could explain a dissociation between the proximal mediator of VP-16-induced cytotoxicity (topoisomerase II-DNA complex formation) and cellular death.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Apoptosis , ADN-Topoisomerasas de Tipo II/metabolismo , Etopósido/farmacología , Proteínas de Neoplasias/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antineoplásicos Fitogénicos/farmacocinética , Neoplasias Encefálicas/metabolismo , ADN de Neoplasias/efectos de los fármacos , ADN de Neoplasias/metabolismo , Resistencia a Antineoplásicos , Etopósido/farmacocinética , Humanos , Células Tumorales Cultivadas/efectos de los fármacos , Ensayo de Tumor de Célula Madre
17.
Pediatr Neurosurg ; 22(5): 274-9, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7547461

RESUMEN

Hemangiopericytomas (HPs) are rare tumors, about 10% of which occur in children. Since 1988, 2 children with intracranial HP have been seen at the University of Texas M.D. Anderson Cancer Center. The patients presented at ages 2 weeks and 1 month. Both were treated with surgery alone. We also review 4 cases previously reported in the literature; at presentation, those patients were ages 2 days to 9 months. Infantile HPs have a better prognosis than do those that occur in adults, and an improved outcome is also evident for intracranial lesions. Tumors that occur in the neonatal period may be treated with surgery alone; however, those that occur after the neonatal period may be more likely to recur.


Asunto(s)
Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/patología , Encéfalo/patología , Hemangiopericitoma/diagnóstico , Hemangiopericitoma/patología , Encéfalo/cirugía , Neoplasias Encefálicas/cirugía , Hemangiopericitoma/cirugía , Humanos , Lactante , Imagen por Resonancia Magnética , Masculino , Invasividad Neoplásica , Tomografía Computarizada por Rayos X
19.
J Biol Chem ; 268(4): 2946-52, 1993 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-8094079

RESUMEN

We observed increased levels of mdr-1 mRNA and its protein product P-glycoprotein (Pgp) in the human colon carcinoma cell line, LS 180, and its drug-resistant sublines, LS 180-Ad50 and LS 180-Vb2, after treatment with the Pgp antagonists, verapamil, nifedipine, and cyclosporin A. Increases in mdr-1 RNA were observed within 8 h of the addition of the Pgp antagonists and continued to rise over time. Peak levels were attained after several weeks and were sustained for the duration of treatment up to several months, with a rapid decline in mdr-1 mRNA levels after removal of the Pgp antagonist. Corresponding changes in Pgp were demonstrated with addition and removal of the Pgp antagonists. Increased mdr-1 mRNA was also seen with two other calcium channel blockers, nicardipine and diltiazem, but not with the Pgp antagonists, quinidine and chlorpromazine. Treatment with verapamil or nifedipine was associated with electron microscopic changes consistent with increased differentiation and resulted in increased carcinoembryonic antigen expression, suggesting that the increase in mdr-1 expression was associated with the process of differentiation. Nuclear runoff experiments and inhibition of new RNA synthesis with actinomycin D treatment failed to detect an increase in mdr-1 transcription or stabilization of the mdr-1 mRNA suggesting that the effect of these agents is mediated posttranscriptionally within the nucleus.


Asunto(s)
Resistencia a Medicamentos , Glicoproteínas de Membrana/antagonistas & inhibidores , Glicoproteínas de Membrana/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP , Diferenciación Celular/efectos de los fármacos , División Celular/efectos de los fármacos , Técnica del Anticuerpo Fluorescente , Expresión Génica/efectos de los fármacos , Humanos , Técnicas In Vitro , Nifedipino/farmacología , ARN Mensajero/genética , ARN Mensajero/metabolismo , Células Tumorales Cultivadas , Verapamilo/farmacología
20.
J Natl Cancer Inst ; 84(9): 711-6, 1992 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-1349044

RESUMEN

BACKGROUND: Multidrug resistance (MDR) mediated by high levels of mdr-1 (also known as PGY1)/P-glycoprotein (Pgp) has been studied in tissue culture systems; however, most tumor samples which express mdr-1/Pgp have much lower levels. PURPOSE: We wanted to determine if levels seen clinically could be detected by commonly used methods and to determine if these levels conferred MDR reversible by Pgp antagonists. METHODS: We studied multi-drug-resistant cell lines and sublines with levels of mdr-1/Pgp expression comparable to those seen clinically. We evaluated the expression of mdr-1 RNA by Northern blot analysis, slot blot analysis, polymerase chain reaction (PCR) analysis, and in situ hybridization. We evaluated protein expression by immunofluorescence, immunohistochemistry, fluorescence-activated cell sorting, and immunoblotting analyses. Drug resistance and reversibility were determined by cell growth during continuous drug exposure. RESULTS: In most cases, the low level of mdr-1/Pgp present in these cell lines could be detected by each method, but the assays were at the limit of sensitivity for all methods except the PCR method. These low levels of mdr-1/Pgp are capable of conferring MDR, which can be antagonized by verapamil. CONCLUSIONS: Levels of mdr-1/Pgp similar to those found in clinical samples can be detected by each of these methods, but the PCR method was the most sensitive and most reliably quantitative. IMPLICATIONS: In vitro sensitization by the addition of verapamil in cell lines with these low levels of mdr-1/Pgp suggests that clinically detected levels may confer drug resistance in vivo.


Asunto(s)
Neoplasias del Colon/fisiopatología , Resistencia a Medicamentos , Glicoproteínas de Membrana/análisis , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP , Citometría de Flujo , Expresión Génica , Humanos , Inmunohistoquímica , Técnicas In Vitro , Glicoproteínas de Membrana/genética , Hibridación de Ácido Nucleico , Reacción en Cadena de la Polimerasa , ARN Mensajero/genética , ARN Neoplásico/genética , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...